Joly Pascal, Benichou Jacques, Lok Catherine, Hellot Marie France, Saiag Philippe, Tancrede-Bohin Emmanuelle, Sassolas Bruno, Labeille Bruno, Doutre Marie Sylvie, Gorin Isabelle, Pauwels Christine, Chosidow Olivier, Caux Frédéric, Estève Eric, Dutronc Yves, Sigal Michèle, Prost Catherine, Maillard Hervé, Guillaume Jean Claude, Roujeau Jean Claude
Department of Dermatology, Institut National de la Santé et de la Récherche Médicale U 519, University of Rouen, Rouen, France.
Arch Dermatol. 2005 Jun;141(6):691-8. doi: 10.1001/archderm.141.6.691.
To identify the prognostic factors of bullous pemphigoid (BP).
Prospective study of patients with BP included in a randomized, controlled trial.
Twenty dermatology departments in France. Patients One hundred seventy patients with BP initially treated with a 40-g/d dosage of clobetasol propionate cream (testing sample) and 171 patients initially treated with oral corticosteroids at a dosage of 0.5 or of 1.0 mg/kg per day, depending on the extent of BP (validation samples).
The end point was overall survival during the first year after BP diagnosis. From the testing sample, associations of clinical and biological variables with overall survival were assessed using univariate and multivariate analyses. Selected predictors were included in a prognostic model. To verify that these predictors were not dependent on the treatment used, the model was then validated independently on the 2 series of BP patients treated with oral corticosteroids.
Median age of the BP patients included in the testing sample was 83 years. The 1-year Kaplan-Meier survival rate was 74%. From univariate analysis, the main deleterious predictors were demographic factors (ie, older age and female sex), associated medical conditions (ie, cardiac insufficiency, history of stroke, and dementia), and low Karnofsky score, which is a measure of the patient's general condition. No factors directly related to BP, in particular extent of cutaneous lesions, were shown to be related to the patients' prognosis. From multivariate analysis, only older age (P = .02) and low Karnofsky score (P<.001) appeared independently predictive of death. From the Cox model including these 2 predictors, the predicted 1-year survival rates were 90% (95% confidence interval [CI], 85%-96%) for patients 83 years or younger with Karnofsky score greater than 40, 79% (95% CI, 69%-90%) for patients older than 83 years with Karnofsky score greater than 40, 65% (95% CI, 50%-86%) for patients 83 years or younger with Karnofsky score of 40 or less, and 38% (95% CI, 26%-57%) for patients older than 83 years with Karnofsky score of 40 or less. Kaplan-Meier survival distributions of patients from the validation samples appeared clearly separated according to these 4 categories and were in close agreement with corresponding predicted 1-year survival rates obtained from the testing sample.
The prognosis of patients with BP is influenced by age and Karnofsky score. These predictors are easy to use and should facilitate the management of BP.
确定大疱性类天疱疮(BP)的预后因素。
对纳入一项随机对照试验的BP患者进行前瞻性研究。
法国的20个皮肤科。患者170例BP患者最初接受每日40g丙酸氯倍他索乳膏治疗(测试样本),171例患者根据BP的严重程度最初接受每日0.5或1.0mg/kg的口服糖皮质激素治疗(验证样本)。
终点为BP诊断后第一年的总生存率。从测试样本中,使用单因素和多因素分析评估临床和生物学变量与总生存率的相关性。选择的预测因素被纳入一个预后模型。为了验证这些预测因素不依赖于所使用的治疗方法,然后在2组接受口服糖皮质激素治疗的BP患者中独立验证该模型。
测试样本中BP患者的中位年龄为83岁。1年的Kaplan-Meier生存率为74%。单因素分析显示,主要的有害预测因素为人口统计学因素(即年龄较大和女性)、相关的内科疾病(即心脏功能不全、中风病史和痴呆)以及低卡诺夫斯基评分,这是衡量患者一般状况的指标。没有显示出与BP直接相关的因素,特别是皮肤病变的严重程度,与患者的预后相关。多因素分析显示,只有年龄较大(P = .02)和低卡诺夫斯基评分(P<.001)独立预测死亡。在包含这2个预测因素的Cox模型中,83岁及以下且卡诺夫斯基评分大于40的患者预测1年生存率为90%(95%置信区间[CI],85%-96%),83岁以上且卡诺夫斯基评分大于40的患者为79%(95%CI,69%-90%),83岁及以下且卡诺夫斯基评分为40或更低的患者为65%(95%CI,50%-86%),83岁以上且卡诺夫斯基评分为40或更低的患者为38%(95%CI,26%-57%)。验证样本中患者的Kaplan-Meier生存分布根据这4个类别明显分开,并且与从测试样本中获得的相应预测1年生存率密切一致。
BP患者的预后受年龄和卡诺夫斯基评分的影响。这些预测因素易于使用,应有助于BP的管理。